According to the latest statistics released by private placement network on the 31st, as of the 30th, 18 10 billion private placements had conducted large-scale research in December, and 35 10 billion private placements had conducted research five times or more in December, with a total of 63 stocks investigated.
From the performance of these investigated stocks, most of them are blue chip stocks. Among them, there were 50 companies with positive year-on-year growth of net profit attributable to the parent company, and 13 listed companies with year-on-year doubling of net profit attributable to the parent company in the third quarter, including Yanan Bicon Pharmaceutical Listed Company(002411) , Teyi Pharmaceutical Group Co.Ltd(002728) , Hunan Jiudian Pharmaceutical Co.Ltd(300705) , Qingdao Haier Biomedical Co.Ltd(688139) in the pharmaceutical and biological industry and inbor, Landai Technology Group Corp.Ltd(002765) , Foryou Corporation(002906) in the automotive industry. Among them, Yanan Bicon Pharmaceutical Listed Company(002411) and inbor’s net profit attributable to the parent increased the most year-on-year, 4672.62% and 929.34% respectively.
Only five of the 10 billion private placement’s stock markets surveyed in December were worth more than 50 billion yuan, and most of them were worth between 10-50 billion yuan, accounting for nearly 43%, and nearly 50% below 50 billion yuan. This shows that 10 billion private equity research prefers small and medium-sized stocks and tends to look for opportunities in small and medium-sized stocks.
From the perspective of research direction, 10 billion private placement has paid high attention to the pharmaceutical stocks that were “neglected” before. According to the data of private placement network, among all stocks, 10 billion private placement investigated the most pharmaceutical stocks in December, reaching 11, including Huadong Medicine Co.Ltd(000963) , Livzon Pharmaceutical Group Inc(000513) , Qingdao Haier Biomedical Co.Ltd(688139) , Yanan Bicon Pharmaceutical Listed Company(002411) , China Reform Health Management And Services Group Co.Ltd(000503) , Zhejiang Xianju Pharmaceutical Co.Ltd(002332) . The net profit of these stocks attributable to the parent company in the third quarter increased positively year-on-year, of which, Qingdao Haier Biomedical Co.Ltd(688139) , Yanan Bicon Pharmaceutical Listed Company(002411) , Hunan Jiudian Pharmaceutical Co.Ltd(300705) more than doubled.
From the performance of individual stocks, most of the pharmaceutical stocks surveyed by the 10 billion private placement in December rose in December, the highest increase was 122% in China Reform Health Management And Services Group Co.Ltd(000503) December, and more than 40% in Jinghua Pharmaceutical Group Co.Ltd(002349) , Shandong Xinhua Pharmaceutical Company Limited(000756) , Jiangxi Synergy Pharmaceutical Co.Ltd(300636) December.
In addition, 10 billion private placement has maintained a concentrated focus on hot sectors such as mechanical equipment, architectural decoration, electronics and automobiles. Eight stocks in the mechanical equipment industry have been investigated by 10 billion private placement, including Fujian Snowman Co.Ltd(002639) , Wuhan Dr Laser Technology Corp.Ltd(300776) , Guoanda Co.Ltd(300902) , Moon Environment Technology Co.Ltd(000811) . Six stocks in the building decoration industry have been investigated by 10 billion private placement, including Shanghai Fengyuzhu Culture Technology Co.Ltd(603466) , Shenzhen Capol International&Associatesco.Ltd(002949) , Hangxiao Steel Structure Co.Ltd(600477) .
(Xinhua Finance)
